A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model
Abstract Introduction New therapeutic strategies to modulate the immune response of human and equine allergic asthma are still under extensive investigation. Immunomodulating agents stimulating T‐regulatory cells offer new treatment options beyond conventional symptomatic treatment or specific immun...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-03-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.198 |
| _version_ | 1818989085389225984 |
|---|---|
| author | John Klier Sabine Geis Jeanette Steuer Katharina Geh Sven Reese Sebastian Fuchs Ralf S. Mueller Gerhard Winter Heidrun Gehlen |
| author_facet | John Klier Sabine Geis Jeanette Steuer Katharina Geh Sven Reese Sebastian Fuchs Ralf S. Mueller Gerhard Winter Heidrun Gehlen |
| author_sort | John Klier |
| collection | DOAJ |
| description | Abstract Introduction New therapeutic strategies to modulate the immune response of human and equine allergic asthma are still under extensive investigation. Immunomodulating agents stimulating T‐regulatory cells offer new treatment options beyond conventional symptomatic treatment or specific immunotherapy for human and equine allergic airway diseases, with the goal of a homoeostatic T‐helper cell balance. The aim of this study was to evaluate the effects of a nebulized gelatin nanoparticle‐CpG formulation (CpG‐GNP) with and without specific allergens for the treatment of spontaneous allergic equine asthma as a model for human asthma. Methods Twenty equine asthma‐affected horses were treated either with CpG‐GNP alone or CpG‐GNP with allergens. Two specific allergens were selected for each horse based on history and an in‐vitro test. Each horse received seven administrations of the respective nebulized composition and was examined before treatment, immediately after and 6 weeks after the treatment course. Results Clinical parameters such as breathing rate, indirect interpleural measurement, arterial blood gases, amount of tracheal mucus and percentage of neutrophils and cytokines in tracheal washes and serum samples were evaluated. Treatment with CpG‐GNP alone as well as in combinations with relevant allergens resulted in clinical improvement of nasal discharge, breathing rate, amount of secretion and viscosity, neutrophil percentage and partial oxygen pressure directly after and 6 weeks after treatment. There were no significant differences between the two treatments in clinical parameters or local cytokine profiles in the tracheal wash fluid (IL‐10, IFN‐g, and IL‐17). IL‐4 concentrations decreased significantly in both groups. Conclusion Nonspecific CpG‐GNP‐based immunotherapy shows potential as a treatment for equine and possibly also human allergic asthma. |
| first_indexed | 2024-12-20T19:32:52Z |
| format | Article |
| id | doaj.art-7199a4a56761465c9541bb56842e68b3 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-12-20T19:32:52Z |
| publishDate | 2018-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-7199a4a56761465c9541bb56842e68b32022-12-21T19:28:44ZengWileyImmunity, Inflammation and Disease2050-45272018-03-0161819610.1002/iid3.198A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal modelJohn Klier0Sabine Geis1Jeanette Steuer2Katharina Geh3Sven Reese4Sebastian Fuchs5Ralf S. Mueller6Gerhard Winter7Heidrun Gehlen8Centre for Clinical Veterinary MedicineEquine Clinic, Ludwig‐Maximilians‐UniversityMunichGermanyCentre for Clinical Veterinary MedicineEquine Clinic, Ludwig‐Maximilians‐UniversityMunichGermanyCentre for Clinical Veterinary MedicineEquine Clinic, Ludwig‐Maximilians‐UniversityMunichGermanyDepartment of PharmacyPharmaceutical Technology and Biopharmaceutics, Ludwig‐Maximilians‐UniversityMunichGermanyDepartment of Veterinary Science, Institute of Anatomy, Histology and EmbryologyLudwig‐Maximilians‐UniversityMunichGermanyDepartment of PharmacyPharmaceutical Technology and Biopharmaceutics, Ludwig‐Maximilians‐UniversityMunichGermanyCentre for Clinical Veterinary Medicine, Small Animal Medicine ClinicLudwig‐Maximilians‐UniversityMunichGermanyDepartment of PharmacyPharmaceutical Technology and Biopharmaceutics, Ludwig‐Maximilians‐UniversityMunichGermanyDepartment of Veterinary Medicine, Equine Clinic, Surgery and RadiologyFree University of BerlinBerlinGermanyAbstract Introduction New therapeutic strategies to modulate the immune response of human and equine allergic asthma are still under extensive investigation. Immunomodulating agents stimulating T‐regulatory cells offer new treatment options beyond conventional symptomatic treatment or specific immunotherapy for human and equine allergic airway diseases, with the goal of a homoeostatic T‐helper cell balance. The aim of this study was to evaluate the effects of a nebulized gelatin nanoparticle‐CpG formulation (CpG‐GNP) with and without specific allergens for the treatment of spontaneous allergic equine asthma as a model for human asthma. Methods Twenty equine asthma‐affected horses were treated either with CpG‐GNP alone or CpG‐GNP with allergens. Two specific allergens were selected for each horse based on history and an in‐vitro test. Each horse received seven administrations of the respective nebulized composition and was examined before treatment, immediately after and 6 weeks after the treatment course. Results Clinical parameters such as breathing rate, indirect interpleural measurement, arterial blood gases, amount of tracheal mucus and percentage of neutrophils and cytokines in tracheal washes and serum samples were evaluated. Treatment with CpG‐GNP alone as well as in combinations with relevant allergens resulted in clinical improvement of nasal discharge, breathing rate, amount of secretion and viscosity, neutrophil percentage and partial oxygen pressure directly after and 6 weeks after treatment. There were no significant differences between the two treatments in clinical parameters or local cytokine profiles in the tracheal wash fluid (IL‐10, IFN‐g, and IL‐17). IL‐4 concentrations decreased significantly in both groups. Conclusion Nonspecific CpG‐GNP‐based immunotherapy shows potential as a treatment for equine and possibly also human allergic asthma.https://doi.org/10.1002/iid3.198allergic asthmaextrinsic asthmaheavesinhalationneutrophilic asthma |
| spellingShingle | John Klier Sabine Geis Jeanette Steuer Katharina Geh Sven Reese Sebastian Fuchs Ralf S. Mueller Gerhard Winter Heidrun Gehlen A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model Immunity, Inflammation and Disease allergic asthma extrinsic asthma heaves inhalation neutrophilic asthma |
| title | A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model |
| title_full | A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model |
| title_fullStr | A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model |
| title_full_unstemmed | A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model |
| title_short | A comparison of nanoparticulate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model |
| title_sort | comparison of nanoparticulate cpg immunotherapy with and without allergens in spontaneously equine asthma affected horses an animal model |
| topic | allergic asthma extrinsic asthma heaves inhalation neutrophilic asthma |
| url | https://doi.org/10.1002/iid3.198 |
| work_keys_str_mv | AT johnklier acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT sabinegeis acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT jeanettesteuer acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT katharinageh acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT svenreese acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT sebastianfuchs acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT ralfsmueller acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT gerhardwinter acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT heidrungehlen acomparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT johnklier comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT sabinegeis comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT jeanettesteuer comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT katharinageh comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT svenreese comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT sebastianfuchs comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT ralfsmueller comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT gerhardwinter comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel AT heidrungehlen comparisonofnanoparticulatecpgimmunotherapywithandwithoutallergensinspontaneouslyequineasthmaaffectedhorsesananimalmodel |